首页> 美国卫生研究院文献>Pulmonary Circulation >The impact of pulmonary arterial hypertension-targeted therapy on survival in Chinese patients with idiopathic pulmonary arterial hypertension
【2h】

The impact of pulmonary arterial hypertension-targeted therapy on survival in Chinese patients with idiopathic pulmonary arterial hypertension

机译:肺动脉高压靶向治疗对中国特发性肺动脉高压患者生存的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The survival rates of Chinese patients with idiopathic pulmonary arterial hypertension (IPAH) and familial pulmonary arterial hypertension (PAH) on conventional therapy at 1 and 3 years were 68.0% and 38.9%, respectively. Our aim was to update recent knowledge on the demographics, clinical course, hemodynamic features, disease management, and survival of adult patients with IPAH. This retrospective and observational study was conducted at the largest tertiary referral center in China. Ninety patients with IPAH who underwent initial evaluation at Fu Wai Hospital from January 2006 through November 2009 were retrospectively enrolled. The primary outcome was death. Statistical analyses used included independent sample t test, nonparametric test, Kaplan-Meier method, and Cox proportional hazards analysis. Of the 90 patients enrolled, the median age was 32 years with female predominance. The median interval from onset of symptoms to diagnosis was 14 months. Patients exhibited severe exercise limitation and hemodynamic abnormalities at diagnosis. Only 10.6% had a positive vasoreactivity test, while calcium channel blockers were given to 22.2% of patients. Fifty-nine patients (65.6%) received PAH-targeted therapies during follow-up. Our survival rates of 84.1%, 73.7%, and 70.6% at 1-, 2-, and 3-years compared favorably with predicted survival based on the National Institutes of Health equation which showed 1-, 2-, and 3-years survival rates of 67.7%, 55.9%, and 47%, respectively. For the patients receiving conventional therapy solely, the 1- and 3-years survival rates were 67.0% and 49.3%, respectively. Younger age, lower body mass index, presence of pericardial effusion, and absence of PAH-targeted therapy were independently associated with mortality. We concluded that patients with IPAH were still diagnosed too late, and while survival rates have improved in the modern treatment era, there is still room for improvement.
机译:中国特发性肺动脉高压(IPAH)和家族性肺动脉高压(PAH)常规治疗1年和3年生存率分别为68.0%和38.9%。我们的目的是更新有关IPAH成年患者的人口统计学,临床过程,血液动力学特征,疾病管理和生存的最新知识。这项回顾性和观察性研究是在中国最大的三级转诊中心进行的。回顾性分析了2006年1月至2009年11月在富威医院接受初步评估的90例IPAH患者。主要结果是死亡。使用的统计分析包括独立样本t检验,非参数检验,Kaplan-Meier方法和Cox比例风险分析。在入组的90例患者中,女性年龄中位数为32岁。从症状发作到诊断的中位间隔为14个月。患者在诊断时表现出严重的运动受限和血液动力学异常。只有10.6%的患者血管反应性测试为阳性,而22.2%的患者给予了钙通道阻滞剂。随访期间有59名患者(65.6%)接受了以PAH为靶标的治疗。根据美国国立卫生研究院(National Institutes of Health)方程显示的1年,2年和3年生存率,我们在1年,2年和3年生存率分别为84.1%,73.7%和70.6%。比率分别为67.7%,55.9%和47%。仅接受常规治疗的患者的1年和3年生存率分别为67.0%和49.3%。年龄较小,体重指数较低,是否存在心包积液以及是否缺乏针对PAH的治疗与死亡率独立相关。我们得出的结论是,IPAH患者仍被诊断为时过晚,尽管在现代治疗时代生存率有所提高,但仍有改善的空间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号